September is National Cholesterol Education Month, an annual observance aimed at raising awareness about the importance of managing cholesterol levels. The month is dedicated to educating the public about the heart disease risks associated with high cholesterol and the steps individuals can take to help maintain healthy levels.   It’s the perfect time to meet the animated characters called the “Lipid Lurkers”—a visual representation of an often-unnoticed risk lurking in patients’ artery walls. While they may look small and silly, they represent a very real and dangerous health threat. Fat and cholesterol are types of lipids transported through the blood. Certain types of lipids, particularly LDL-C or “bad” cholesterol, can lead to buildup of plaque in the arteries, increasing the risk of heart disease or stroke.   This campaign was created to help educate and empower the nearly 100 million U.S. adults with high LDL-C—especially those who can’t take statins (medications to lower cholesterol) or who have uncontrolled cholesterol and haven’t reached their target levels despite treatment.   Now, there are solutions that offer an alternative to statins— additional options for lowering LDL cholesterol—while also lowering the risk of heart attacks and heart procedures like stent placement or bypass surgery    On Wednesday, September 10, LeAnne Bloedon, MS, RD, Vice President, Clinical Development at Esperion Therapeutics, will be available to discuss the havoc that too much bad cholesterol can cause inside artery walls—and how to lower your cholesterol.   She’ll also outline:   What high LDL cholesterol really does to your body (and why it’s often silent) Why managing cholesterol matters before your first cardiovascular event How the “Lipid Lurkers” campaign is making heart health more accessible, relatable, and even fun Who’s at risk—and what new options are available beyond traditional statins https://www.fiercepharma.com/marketing/esperions-lipid-lurkers-campaign-sheds-light-high-ldl-cholesterol-hiding-artery-walls

#septembercholesterol #cholesterol

The post September is National Cholesterol Education Month THE PERFECT TIME TO MEET THE “LIPID LURKERS” Tiny Troublemakers Wreaking Havoc in Your Arteries appeared first on Good News!.

BIO:
Dr. Karsh earned his MD from The Chicago Medical School. He completed his General Surgical training at The University of Colorado Health Sciences Center and his Urology Residency at the Brigham and Women’s Hospital/Harvard Medical School.
Dr. Karsh was a co-founder of The Urology Center of Colorado which was recently acquired by Advent Health Urology Denver where he serves as an attending Urologist and Director of Research. He is a certified principal investigator with an experience of more than 275 clinical trials. Dr. Karsh has authored a number of peer-reviewed publications and serves on the editorial boards for “Bladder Cancer.” He is an active member of the AUA, , ASCO, BCAN, SUO,SWOG and the Denver Academy of Surgeons. Dr. Karsh served on the board of SUO from 2010-2020 and served on the bladder cancer subcommittee during that time.

Ferring Pharmaceuticals, Inc.

Website for more information:                           ADSTILADRIN

#cancer #bladdercancer #drkarsh #mike

The post BLADDER CANCER IS THE SIXTH MOST COMMON CANCER IN THIS COUNTRY? appeared first on Good News!.

Although pain is one of the most common reasons that people visit the doctor, managing it can be complicated.

So, what’s a patient—or a doctor – to do?  Here to talk about the unmet need in treating acute pain is Dr. David Dalury, Professor of Orthopedic Surgery (Emeritus) at the University of Maryland.

vrtx.com 

The results show how patients’ lives are affected by acute pain:

70% say it limits them from walking and exercising.
69% says it limits their sleep.
65% says it affects their hobbies and leisure activities.
65% say it made them feel irritable or emotionally drained.
Patients reported missing an average of 19 working days annually.

Pain is one of the most common reasons that people visit the doctor; however, treatment options for the various types and causes of pain remain limited.i,ii,iii

Approximately 40 million Americans with acute pain are prescribed an opioid to manage their discomfort each year.vii Although opioids can be effective, they also carry a labeled risk of addiction.viii In fact, roughly 85,000 U.S. adults are expected to develop opioid use disorder (OUD) within a year of their prescribed treatment of acute pain.vii

Health care providers may prescribe either acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) as alternatives for milder pain or additions to opioids for severe acute pain; while these treatments are generally well tolerated, they may have limited effectiveness, particularly for moderate-to-severe acute pain.viii,ix

The survey also shows that:

77% of patients say they are interested in trying a different pain medication if they experience acute pain again.
52% say they are seeking a new pain medication with fewer side effects than their last medication.
31% say they stopped taking their medication before their pain was resolved.
On Wednesday, December 4th, Dr. David Dalury Professor of Orthopedic Surgery (Emeritus) at the University of Maryland will be available to discuss the survey results and help raise awareness about the unmet need in current pain management options and offer solutions.

Tell me about the State of Pain survey. What did it evaluate?​

Can you tell us some of the key findings? What did you learn? ​

Why is it important to focus on pain management right now? ​

Where can people learn more about the State of Pain survey?​

Interview is courtesy: Vertex Pharmaceuticals

#drdaviddalury #vertexpharmaceuticals #pain #orthopedicsurgery

The post NEW SURVEY ON PAIN SHOWS HOW IT DISRUPTS EVERYDAY LIFE & WHY THERE’S A NEED FOR ALTERNATIVE TREATMENTS appeared first on Good News!.

The post Asian Pacific Association for Laser Medicine and Surgery…October 25-27, 2024 appeared first on Good News!.

Non-small cell lung cancer (NSCLC) is the most common form, accounting for approximately 85% of all lung cancers.2 Many people diagnosed with early-stage NSCLC have surgery to remove the cancer; however, for approximately half of these patients, the cancer unfortunately returns.3 Experts agree there is an urgent need for enhanced screening uptake — which has hovered around five percent in recent years amongst those eligible to receive it4 — as well as improved treatment options in early-stage NSCLC to help prevent devastating cancer recurrences.

Studies have shown that treatments beyond chemotherapy, including targeted therapy and now immunotherapy – a type of personalized cancer treatment that activates the immune system to fight cancer – may help improve outcomes for certain patients with early-stage NSCLC after surgery.5 What’s promising is that these studies have now led to U.S. Food and Drug Administration approvals in the post-surgery setting to help reduce the risk of recurrence for patients with specific types of early-stage NSCLC, introducing a new era for these lung cancer patients.

Dr. David Carbone, Professor of Internal Medicine and Director of the James Thoracic Oncology Center at Ohio State University Medical Center will discuss the latest progress, including one of the most recent developments in early-stage lung cancer for patients.

Interview courtesy: Genentech

1 ACS. Key Statistics for Lung Cancer. 2022. Accessed from: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.
2 Molina et al. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc. 2008 May; 83(5): 584–594. Accessed September 27, 2021.
3 Yano T, Okamoto T, Fukuyama S, Maehara Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin
Oncol. 2014;5(5):1048-1054. doi:10.5306/wjco.v5.i5.1048
4 Fedewa SA, Kazerooni EA, Studts JL, et al. State Variation in Low-Dose CT Scanning for Lung Cancer Screening in the United States. JNCI: The Journal of the National Cancer Institute. doi: 10.1093/jnci/djaa170
5 Zappa et al. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016 Jun; 5(3): 288–300. doi:
10.21037/tlcr.2016.06.07.

#davidcarbone #lungcancer #genentech #americancancersociety #factsfigures #disease #aminotherapy #etizolam #go2foundation #nsclc #surgery #chemotherapy #medicine #treatments #patients

The post EXCITING PROGRESS IN DIAGNOSING AND TREATING EARLY-STAGE LUNG CANCER appeared first on Good News!.

zynrelef.com (http://zynrelef.com)

As we are approaching Pain Awareness Month in September, it is a time to highlight the issues of postoperative pain and postoperative pain management in the United States. Recent data shows that 67% of patients filled an opioid prescription between 30 days before through 14 days after surgery. In the past, postoperative pain management has been a one-size-fits all approach and there is an urgent need for it to be more individualized.
While patients routinely are searching for a safe and effective way to manage the pain they experience following surgery, many tell doctors they want to avoid the adverse effects that are commonly experienced by those receiving opioids to reduce their pain. The most common adverse effects are dizziness, nausea and constipation. But even more than that, patients want to avoid any risk of misuse and addiction.
Now there’s been a new development; what some surgeons are calling a “game-changer” for postoperative pain. The FDA recently approved a treatment that works on both inflammation and pain at the surgical site for up to 3 days for those who undergo bunion surgery, hernia repair and total knee replacement surgeries. Clinical trials have shown that this new treatment reduces the need for and can eliminate in many patients, potentially addictive opioids. The safety and efficacy of this new treatment has not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. The new treatment also contains an NSAID (non-steroidal anti-inflammatory drug), a type of medicine which:

can increase the risk of a heart attack or stroke that can lead to death. This risk increases with higher doses and longer use of an NSAID.

cannot be used during heart bypass surgery.

can increase the risk of gastrointestinal bleeding, ulcers, and tears.

Dr. Alan Rechter, an orthopedic surgeon, will be available to discuss the newest method of effectively managing postoperative pain. He will explain why this latest development is such an important step in helping patients who are undergoing a variety of procedures.
Interview Courtesy: Heron Therapeutics

References:

NCHS, National Vital Statistics System. Estimates for 2020 are based on provisional data. Estimates for 2015-2019 are based on final data (available from: https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm (https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm)).

Santosa KB, Hu HM, Brummett CM, et al. New Persistent Opioid Use Among Older Patients Following Surgery: A Medicare Claims Analysis. Surgery. 2020;167(4):732-742. doi:10.1016/j.surg.2019.04.016

U.S. Food & Drug Administration. Data presented at June 11-12, 2019 Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC).

ZYNRELEF [Package Insert]. San Diego, CA: Heron Therapeutics Inc.; 2021.

Viscusi E, Gimbel JS, Pollack RA, Hu J, Lee G-C. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in bunionectomy: phase III results from the randomized EPOCH 1 study. Reg Anesth Pain Med. 2019;44(7):700-706. doi:10.1136/rapm-2019-100531.

Viscusi E, Minkowitz H, Winkle P, Ramamoorthy S, Hu J, Singla N. HTX-011 reduced pain intensity and opioid consumption versus bupivacaine HCl in herniorrhaphy: results from the phase 3 EPOCH 2 study. Hernia. 2019;23(6):1071-1080. doi:10.1007/s10029-019-02023-6.

BIO-Alan Rechter, M.D.
Orthopedic Surgeon at Orthopaedic Associates
Dr. Alan Rechter is a board-certified orthopedic surgeon and has practiced medicine in Houston since 1995. He joined Orthopaedic Associates in 1999 and has staff privileges at Methodist West & Houston Orthopedic & Spine Hospital in Bellaire. He is a former Clinical Assistant Professor of Orthopedics at the University of Texas Medical School.
Throughout his career, he received numerous awards. He was recognized by Merck Pharmaceuticals as one of the top ranked medical school graduates during his graduating year. He received a prestigious AO International Fellowship in Germany, which affords focused training in the arts of trauma, hand and joint reconstructive surgery.
Dr. Rechter received his Bachelor’s degree from the University of South Florida and his medical degree from Creighton University School of Medicine in Omaha, NE. Dr. Rechter completed his training in orthopedic surgery at the University of Texas in Houston after being Chief Resident for the 1998-1999 academic year.

ZYNRELEF is approved for use in adults to reduce pain for up to 3 days after removal of bunions, groin hernia repair, and total knee replacement. ZYNRELEF is applied into the wound at the time of surgery.
Important Safety Information
ZYNRELEF contains an NSAID (non-steroidal anti-inflammatory drug), a type of medicine which:
• can increase the risk of a heart attack or stroke that can lead to death. This risk increases with higher doses and longer use of an NSAID.
• cannot be used during heart bypass surgery.
• can increase the risk of gastrointestinal bleeding, ulcers, and tears.

ZYNRELEF should also not be used:
• if you are allergic to any components of ZYNRELEF, aspirin or other NSAIDs (such as ibuprofen or naproxen), or have had an asthma attack, hives, or other allergic reaction after taking any of these medicines.
• as a paracervical block, during childbirth.

The most common side effects of ZYNRELEF are constipation, vomiting, and headache.

The medicines in ZYNRELEF (a local anesthetic and an NSAID) can affect the nervous and cardiovascular system; may cause liver or kidney problems; may reduce the effects of some blood pressure medicines; should be avoided if you have severe heart failure; may cause a rare blood disorder, or life-threatening skin or allergic reactions; may harm your unborn baby if received at 20 weeks of pregnancy or later; and may cause low red blood cells (anemia).
Tell your healthcare provider about all your medical conditions and about all the medicines you take including prescription or over-the-counter medicines, vitamins, or herbal supplements to discuss if ZYNRELEF is right for you

#alan #rechter #death #overdose #prescription #opioids #cdc #pain #awareness #houston #texas #surgery #zynrelef #heron #therapeutics #fda #medicine #safety #asthma #headache

The post AT A TIME WHEN DRUG OVERDOSE DEATHS ARE CLIMBING A NEW TREATMENT FOR POSTOPERATIVE PAIN MAY HELP REDUCE THE NEED FOR OPIOIDS AFTER SURGERY appeared first on Good News!.

Sun safety habits are important all times of year, and that includes in the winter. Winter activities, such as snow skiing, can result in significant exposure to ultraviolet (UV) radiation from the sun – the leading cause of skin cancers – as UV rays reflect off surfaces, even on cloudy and hazy days. This winter, sun exposure may be a special concern as people spend more time outside, due to COVID-19.

Of particular concern is melanoma, a form of skin cancer. When diagnosed in its early stages, melanoma can be treatable, but it may come back in 20-30% of patients. And in its advanced stages, melanoma can be deadly.

Dr. Sigrun Hallmeyer, a Chicago-based oncologist discusses:
• Why sun safety is important all year round
• Warning signs of skin cancer, including melanoma
• The importance of treatment if someone is diagnosed with melanoma
• Treatment options to help prevent a skin cancer called melanoma from coming back after it has been removed by surgery

Interview is courtesy: Bristol Myers Squibb

#winter #sigrun #hallmeyer #oncologist #surgery #chicago #sun #safety #safe #hidden #dangers #danger #exposure #habits #snow #skiing #result #ultraviolet #uv #radiation #skin #cancer #rays #surface #covid #melanoma #treatment

The post YOU MAY NOT THINK ABOUT SUN SAFETY IN WINTER… BUT YOU SHOULD appeared first on Good News!.

Listen to “Dr. Ronald Caplan” on Spreaker.

www.careoftheolderperson.com shares the Good News of Ronald M. Caplan
MD, CM, FACS, FACOG, FRCS(C), Clinical Associate Professor Emeritus Obstetrics and Gynecology, Weill Medical College of Cornell University

Ronald M. Caplan MD is an Obstetrician Gynecologist and medical author.

He did his medical and postgraduate training at McGill University, where his interest in renal disease in pregnancy and homotransplantation culminated in the first delivery of a baby from a mother who had received a deceased donor kidney transplant.

After serving on the Faculty of McGill University, he transferred to New York City, and a long career at the Joan and Sanford I. Weill Medical College of Cornell University , where he became one of the early proponents of minimally invasive surgery, and where he is now Clinical Associate Professor Emeritus of Obstetrics and Gynecology.

He is a Fellow of the American College of Surgeons, the American College of Obstetrics and Gynecology, and the Royal College of Surgeons (Canada).

He previously edited the textbooks Principles of Obstetrics, which was translated into both Spanish and Portuguese, and Advances in Obstetrics and Gynecology, which was translated into Spanish. He authored another four mass market medical books in multiple editions. Prestigious medical and comprehensive libraries around the world hold copies of his work.

#dr #dr. #doctor #doc #ronald #caplan #care #older #person #careofolderperson #clinical #associate #professor #emeritus #obstetrics #gynecology #medical #mcgill #md #university #royal #college #surgeons #surgeon #obstetrics #canada #american #surgery #cornell #world

The post Ronald M. Caplan MD, www.careoftheolderperson.com appeared first on Good News!.

JOINING US NOW DURING HEART HEALTH MONTH IS INTERVENTIONAL CARDIOLOGIST AND MEMBER OF THE ASSOCIATION OF BLACK CARDIOLOGISTS DR. WAYNE BATCHELOR TO TELL US A LITTLE MORE ABOUT CORONARY ARTERY DISEASE, AND TO SHARE SOME TIPS FOR LIVING A HEART HEALTHY LIFESTYLE.

BIO: Dr. Wayne Batchelor received his B.A. and Doctorate of Medicine degrees summa cum laude at Queen’s University in Kingston, Ontario in Canada. He then completed a Comprehensive Internal Medicine Residency and Fellowship in Adult Cardiology at the University of Toronto and a fellowship in Interventional Cardiology with a Master’s of Health Science Degree in Clinical Research at Duke University.
He is the incoming Director of Interventional Cardiology and Interventional Cardiology Research at the Inova Heart and vascular Institute in Fairfax, Virginia. He has served on the Medical Faculty as an Assistant Professor of Medicine at the University of Toronto and as Associate Professor of Medicine at the Florida State University College of Medicine and has practiced as an interventional cardiologist at St. Michael’s Hospital in Toronto, Ontario Canada and at the Tallahassee Memorial Hospital in Florida.
Dr. Batchelor has given numerous invited lectures, published over 75 peer-reviewed original abstracts/manuscripts, and contributed multiple book chapters. He is a Fellow of the American College of Cardiology and the Society for Cardiac Angiography and Interventions, and was selected to serve on the American College of Cardiology’s (ACC) D2B (Door to Balloon) Task Force, a national committee charged with improving the rapidity of care for heart attack victims across the U.S. He currently serves on the ACC’s Interventional Cardiology Sectional Leadership Council.
His primary expertise is in structural/valvular heart disease, coronary and peripheral arterial disease, carotid artery disease and clinical research in interventional cardiology. He was instrumental in starting the first structural/valvular heart program at Tallahassee Memorial Hospital and served as Chair of its Interventional Cardiology Council. He has a keen interest in radial artery access percutaneous coronary interventions and has performed more than 4,000 radial access coronary stent procedures.
During his career, he has been recognized as the recipient of a number of awards, including the Dr. and Mrs. Sydney P. Schiff Medal in Surgery, Nathan E. Berry Prize in Urology, Sopman Award for Clinical Excellence and Human Compassion, National Research Fellowship from the Heart and Stroke Foundation of Canada, and the Capital Medical Society’s Outstanding Physician of the Year Award in 2017.
He is certified by the American Board of Internal Medicine in Cardiovascular Disease with added qualifications in Interventional Cardiology.

The post CARDIOVASCULAR DISEASE IS THE LEADING CAUSE OF DEATH AND DISABILITY AMONG ALL AMERICANS, BUT BLACK MEN AND WOMEN ARE MORE LIKELY….. appeared first on Good News!.

The post What Does Peace Mean to You? appeared first on Good News!.